Who Paid My Doc
Joseph Lasky
Pediatric Hematology-Oncology Las Vegas, NV Medical Doctor
NPI 1386680718 CMS profile 107550
1 Breakthrough Way, Las Vegas, NV 89135
General payments
$16,309
Research payments
$7,525
Ownership & investment interest
$0
Research they led as principal investigator
$152,090
Through program year 2025, Joseph Lasky of Las Vegas, NV is reported in the CMS Open Payments database as having received $16,309 across 113 general payments and $7,525 in research payments paid to them. Separately, studies naming them as principal investigator received $152,090 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,812 | 27 | |
| 2024 | General | $1,532 | 26 | |
| 2023 | General | $738 | 17 | |
| 2022 | General | $613 | 9 | |
| 2021 | General | $222 | 3 | |
| 2020 | General | $6,157 | 5 | |
| 2019 | General | $5,235 | 26 | |
| 2019 | Research | $7,525 | 1 |
Beside peers
- Joseph Lasky
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Joseph Lasky were reported at $1,812. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Joseph Lasky | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,235 | $184 | $69–$2,094 | $163 |
| 2020 | $6,157 | $220 | $37–$3,941 | $114 |
| 2021 | $222 | $366 | $63–$4,909 | $132 |
| 2022 | $613 | $181 | $66–$2,775 | $149 |
| 2023 | $738 | $175 | $62–$2,600 | $160 |
| 2024 | $1,532 | $227 | $66–$2,992 | $164 |
| 2025 | $1,812 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
114 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Nevada
Daisy Cortes
Pediatric Hematology-Oncology · Las Vegas, NV
Jenny Gober McDaniel
Pediatric Hematology-Oncology · Las Vegas, NV
Aimee Foord
Pediatric Hematology-Oncology · Las Vegas, NV
Nik Nik Abdul Rashid
Pediatric Hematology-Oncology · Las Vegas, NV
Jerry Reeves
Pediatric Hematology-Oncology · Las Vegas, NV
Waseem Alhushki
Pediatric Hematology-Oncology · Las Vegas, NV
Related records
Pediatric Hematology-Oncology in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.